immunocytochemistry; ERBB2 promoter; AP-2 transcription factor; human
Abstract :
[en] The ERBB2 gene is overexpressed in 30% of breast cancers and this has been correlated with poor prognosis. ERBB2 is upregulated in other cancers such as prostate, pancreas, colon and ovary. In breast cancer cells, the mechanisms leading to ERBB2 gene overexpression are increased transcription and gene amplification. In these cancers, AP-2 transcription factors are involved in ERBB2 overexpression, and AP-2 levels are correlated with p185(c-erbB-2) levels. In this work, we wanted to know if the same molecular mechanisms are responsible for the ERBB2 upregulation in non-breast cancers. We compared ERBB2 gene copy number, p185(c-erbB-2) and mRNA levels with AP-2 levels in several ovary, prostate, colon and pancreas cancer cells. A moderate expression of erbB-2 mRNA and protein were observed in some cells without gene amplification. In contrast to breast cancer cells, AP-2 factors were absent or low in some non-breast cells which did express ERBB2. It is thus likely that AP-2 is not a major player in the increased levels of erbB-2 transcripts in non-breast cancer cells. The transcriptional activity of the ERBB2 promoter in colon and ovary cancer cells was estimated using reporter vectors. The results showed that the promoter regions involved in ERBB2 gene overexpression in breast cancer cells are different from those that lead to the gene upregulation in colon and ovary cancers. In conclusion, our results indicate that different transcriptional and post-transcriptional mechanisms are responsible for the increased levels of erbB-2 transcript and protein in breast and non-breast cancer cells.
Disciplines :
Oncology
Author, co-author :
Vernimmen, D.
Guéders, Maud ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Pisvin, Sonia ; Centre Hospitalier Universitaire de Liège - CHU > Centre de diagnostic moleculaire
Delvenne, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Winkler, Rose ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Language :
English
Title :
Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers
Anttila MA, Kellokoski JK, Moisio KI, Mitchell PJ, Saarikoski S, Syrjanen K, Kosma VM (2000) Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer. Br J Cancer 82: 1974-1983
Bates NP, Hurst HC (1997) Transcriptional regulation of type I receptor tyrosine kinases in the mammary gland. J Mammary Gland Biol Neoplasia 2: 153-163
Bosher JM, Totty NF, Hsuan JJ, Williams T, Hurst HC (1996) A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 13: 1701-1707
Bosher JM, Williams T, Hurst HC (1995) The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci USA 92: 744-747
Buettner R, Kannan P, Imhof A, Bauer R, Yim SO, Glockshuber R, Van Dyke MW, Tainsky MA (1993) An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2. Mol Cell Biol 13: 4174-4185
Child SJ, Miller MK, Geballe AP (1999) Cell type-dependent and -independent control of HER-2/neu translation. Int J Biochem Cell Biol 31: 201-213
Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ, Clinton GM (1998) NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 58: 5123-5129
De Potter CR, Quatacker J, Maertens G, Van Daele S, Pauwels C, Verhofstede C, Eechaute W, Rods H (1989) The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer 44: 969-974
DiGiovanna MP (1999) Clinical significance of HER-2/neu overexpression: Part I. Principles Practice Oncol 13: 1-10
Doherty JK, Bond CT, Hua W, Adelman JP, Clinton GM (1999a) An alternative HER-2/neu transcript of 8 kb has an extended 3'UTR and displays increased stability in SKOV-3 ovarian carcinoma cells. Gynecol Oncol 74: 408-415
Doherty JK, Bond CT, Jardim A, Adelman JP, Clinton GM (1999b) The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc Natl Acad Sci USA 96: 10869-10874
Eloranta JJ, Hurst HC (2002) Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated in vivo. J Biol Chem 277: 30798-30804
Esparis-Ogando A, Diaz-Rodriguez E, Pandiella A (1999) Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. Biochem J 344: 339-348
Fajac A, Benard J, Lhomme C, Rey A, Duvillard P, Rochard F, Bernaudin JF, Riou G (1995) c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. Int J Cancer 64: 146-151
Grooteclaes M, Pasleau F, Dijkmans H, Berzi P, Albert A, Winkler-Gol R (1994) The 6-kilobase c-erbB2 promoter contains positive and negative regulatory elements functional in human mammary cell lines. Cancer Res 54: 4193-4199
Grooteclaes M, Vernimmen D, Plaza S, Pasleau F, Hodzic D, Winkler-Gol R (1999) A new cis element is involved in the HER2 gene overexpression in human breast cancer cells. Cancer Res 59: 2527-2531
Hollywood DP, Hurst HC (1993) A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J 12: 2369-2375
Kapitanovic S, Spaventi R, Poljak L, Kapitanovic M, Pavelic ZP, Gluckman JL, Spaventi S, Pavelic K (1994) High c-erbB-2 protein level in colorectal adenocarcinomas correlates with clinical parameters. Cancer Detect Prev 18: 97-101
Karjalainen JM, Kellokoski JK, Mannermaa AJ, Kujala HE, Moisio KI, Mitchell PJ, Eskelinen MJ, Alhava EM, Kosma VM (2000) Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2alpha in cutaneous melanoma. Br J Cancer 82: 2015-2021
King BL, Carter D, Foellmer HG, Kacinski BM (1992) Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines. Am J Pathol 140: 23-31
Klapper LN, Kirschbaum MH, Sela M, Yarden Y (2000) Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77: 25-79
Kornilova ES, Taverna D, Hoeck W, Hynes NE (1992) Surface expression of erbB-2 protein is post-transcriptionally regulated in mammary epithelial cells by epidermal growth factor and by the culture density. Oncogene 7: 511-519
Lipponen P, Aaltomaa S, Kellokoski J, Ala-Opas M, Kosma V (2000) Expression of activator protein 2 in prostate cancer is related to tumor differentiation and cell proliferation. Eur Urol 37: 573-578
Maniatis T, fritsch E, Sambrook J (1982) Molecular Cloning: a Laboratory Manual. New York: Cold Spring Harb Lab
Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN (2001) Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120: 1713-1719
Maurer CA, Friess H, Kretschmann B, Zimmermann A, Stauffer A, Baer HU, Korc M, Buchler MW (1998) Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 29: 771-777
Miller S, Suen TC, Sexton T, Hung MC (1994) Mechanisms of deregulated HER2/neu expression in breast cancer cell lines. Int J Oncol 4: 599-608
Molina MA, Saez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ, Albanell J, Keenan EJ, Lluch A, Garcia-Conde J, Baselga J, Clinton GM (2002) NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 8: 347-353
Morote J, de Torres I, Caceres C, Vallejo C, Schwartz Jr S, Reventos J (1999) Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatsic prostate cancer. Int J Cancer 84: 421-425
Nakae S, Shimada E, Urakawa T (1993) Study of c-erbB-2 protein and epidermal growth factor receptor expression and DNA ploidy pattern in colorectal carcinoma. J Surg Oncol 54: 246-251
Newman SP, Bates NP, Vernimmen D, Parker MG, Hurst HC (2000) Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 19: 490-497
Nezu M, Sasaki H, Kuwahara Y, Ochiya T, Yamada Y, Sakamoto H, Tashiro H, Yamazaki M, Ikeuchi T, Saito Y, Terada M (1999) Identification of a novel promoter and exons of the c-ERBB-2 gene. Biochem Biophys Res Commun 258: 499-505
Pasleau F, Grooteclaes M, Gol-Winkler R (1993) Expression of the c-erbB2 gene in the BT474 human mammary tumor cell line: measurement of c-erbB2 mRNA half-life. Oncogene 8: 849-854
Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI (1993) The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8: 2917-2923
Ropponen KM, Kellokoski JK, Pirinen RT, Moisio KI, Eskelinen MJ, Alhava EM, Kosma VM (2001) Expression of transcription factor AP-2 in colorectal adenomas and adenocarcinomas; comparison of immunohistochemistry and in situ hybridisation. J Clin Pathol 54: 533-538
Ross JS, Fletcher JA (1999) HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 112: S53-S67
Ross JS, Nazeer T, Church K, Amato C, Figge H, Rifkin MD, Fisher HA (1993) Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer 72: 3020-3028
Ruiz M, Troncoso P, Bruns C, Bar-Eli M (2001) Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer. Clin Cancer Res 7: 4086-4095
Schreiber E, Matthias P, Muller MM, Schaffner W (1989) Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 17: 6419
Scott GK, Chang CH, Erny KM, Xu F, Fredericks WJ, Rauscher III FJ, Thor AD, Benz CC (2000) Ets regulation of the erbB2 promoter. Oncogene 19: 6490-6502
Scott GK, Robles R, Park JW, Montgomery PA, Daniel J, Holmes WE, Lee J, Keller GA, Li WL, Fendly BM et al. (1993) A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 13: 2247-2257
Siegel PM, Ryan ED, Cardiff RD, Muller WJ (1999) Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J 18: 2149-2164
Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M (2000) Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92: 1918-1925
Vernimmen D, Begon D, Salvador C, Gofflot S, Grooteclaes M, Winkler R (2003) Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression. Biochem J 370: 323-329
Yamanaka Y, Friess H, Kobrin MS, Buchler M, Kunz J, Beger HG, Korc M (1993) Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol 24: 1127-1134
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137
Zabrecky JR, Lain T, McKenzie SJ, Carney W (1991) The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 266: 1716-1720